Moleculin Biotech Inc. (NASDAQ: MBRX)
$4.39
+0.1400 ( +3.29% ) 0.6K
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Market Data
Open
$4.39
Previous close
$4.25
Volume
0.6K
Market cap
$9.62M
Day range
$4.12 - $4.30
52 week range
$3.22 - $15.75
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 14 | Oct 06, 2023 |
8-k | 8K-related | 16 | Oct 02, 2023 |
8-k | 8K-related | 16 | Sep 21, 2023 |
8-k | 8K-related | 15 | Sep 18, 2023 |
8-k | 8K-related | 16 | Sep 14, 2023 |
def | Proxies and info statements | 3 | Sep 01, 2023 |
8-k/a | 8K-related | 34 | Aug 23, 2023 |
8-k | 8K-related | 34 | Aug 21, 2023 |
8-k | 8K-related | 15 | Aug 21, 2023 |
pre | Proxies and info statements | 3 | Aug 21, 2023 |